tofacitinib

Overview

Tofacitinib is a small-molecule Janus kinase (JAK) inhibitor that selectively targets JAK1 and JAK3, with some activity against JAK2, thereby blocking downstream signal transducer and activator of transcription (STAT) signaling pathways. Classified under ATC code L04 (immunosuppressants), it was among the first oral JAK inhibitors approved for clinical use and represents a pivotal advance in targeted immunotherapy. By interrupting JAK/STAT-mediated cytokine signaling — including pathways driven by proinflammatory cytokines such as interleukins and interferons — tofacitinib suppresses aberrant immune activation central to a broad range of immune-mediated inflammatory diseases (IMIDs). Its oral bioavailability and pan-JAK inhibitory profile distinguish it from earlier biologics such as adalimumab, etanercept, and rituximab, which require parenteral administration and target discrete extracellular molecules.

Tofacitinib is approved for indications including rheumatoid arthritis (RA), psoriatic arthritis, ulcerative colitis (UC), and ankylosing spondylitis, and has been investigated off-label across numerous dermatologic and inflammatory conditions. As a first-generation JAK inhibitor, it occupies an important position in the evolving therapeutic landscape alongside newer agents such as upadacitinib, baricitinib, abrocitinib, and deucravacitinib. However, regulatory authorities have attached boxed warnings to tofacitinib and the broader JAK inhibitor class regarding risks of serious infections, major adverse cardiovascular events, and malignancy — considerations that continue to shape its clinical application and ongoing real-world safety research.

Focus of Latest Publications

Recent publications on tofacitinib have focused mainly on its real-world use in alopecia areata, ulcerative colitis, inflammatory arthritis, and refractory ocular inflammation, as well as on formulation and mechanistic studies. In alopecia areata, retrospective cohorts evaluated tofacitinib alongside other Janus kinase inhibitors, including baricitinib and ritlecitinib, with outcomes assessed by Severity of Alopecia Tool (SALT) scores through week 24 or after 12 weeks of treatment. These studies reported clinically meaningful hair regrowth in a subset of patients, with better responses in acute or severe disease than in non-acute or less severe disease, and identified tofacitinib treatment as a predictor of super-responder status in one cohort. Patient-reported outcomes such as DLQI/CDLQI and visual analog scale scores also improved in the multicenter study, while adverse events were generally manageable.

In ulcerative colitis, tofacitinib was included in a multicenter real-world comparison with filgotinib and upadacitinib, although the abstract provided does not report the comparative results. Another real-world study examined endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinib, reflecting interest in deeper disease control, but the abstract excerpt does not provide the numerical findings. In skin immune-mediated inflammatory diseases, a large multinational cohort assessed the safety of Janus kinase inhibitors, including tofacitinib, versus conventional immunomodulators and found no increased risk of mortality, major adverse cardiovascular events, venous thromboembolism, or malignancy over 2 years.

Mechanistic and translational studies have also examined how tofacitinib modulates inflammatory pathways. In inflammatory arthritis, tofacitinib was investigated for its effects on T cell activation, polyfunctionality, proliferation, and metabolism. In rheumatoid arthritis macrophages reprogrammed by Csf2/GM-CSF signaling, tofacitinib downregulated GM-CSFRα expression, inhibited STAT5 signaling, reduced oxidative stress and mitochondrial fragmentation, and shifted macrophages toward a regulatory phenotype in patient samples and preclinical models. A case report also described rapid remission of refractory scleritis after starting tofacitinib, although control was not maintained after tapering methotrexate and corticosteroids, and remission was later regained with upadacitinib.

Beyond clinical and mechanistic studies, tofacitinib has been used as a model compound in pharmaceutical research. One study developed a tofacitinib free base tablet and showed comparable dissolution to a marketed reference product at acidic pH, slower but complete dissolution at pH 6.8, and bioequivalent systemic exposure in Beagle dogs under fasted and fed conditions. Another formulation study examined extended-release hydrophilic matrix tablets and found that organic acids could reduce the pH dependence of tofacitinib release through both microenvironmental pH effects and interactions with the drug and polymers.